{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:57:24Z","timestamp":1787320644734,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74840-4","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T14:03:08Z","timestamp":1729346588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between radiation therapy for primary endometrial cancer and risk of second primary malignancies: a retrospective cohort study"],"prefix":"10.1038","volume":"14","author":[{"given":"Yuebo","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"key":"74840_CR1","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1200\/JCO.18.01575","volume":"37","author":"ME Randall","year":"2019","unstructured":"Randall, M. E. et al. Phase III trial: Adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel\/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J. Clin. Oncol. 37, 1810\u20131818 (2019).","journal-title":"J. Clin. Oncol."},{"key":"74840_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","volume":"19","author":"SM de Boer","year":"2018","unstructured":"de Boer, S. M. et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 19, 295\u2013309 (2018).","journal-title":"Lancet Oncol."},{"key":"74840_CR3","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","volume":"380","author":"D Matei","year":"2019","unstructured":"Matei, D. et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl. J. Med. 380, 2317\u20132326 (2019).","journal-title":"N Engl. J. Med."},{"key":"74840_CR4","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1200\/JCO.2013.48.8023","volume":"31","author":"M Onsrud","year":"2013","unstructured":"Onsrud, M. et al. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J. Clin. Oncol. 31, 3951\u20133956 (2013).","journal-title":"J. Clin. Oncol."},{"key":"74840_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","volume":"12","author":"A de Berrington","year":"2011","unstructured":"de Berrington, A. et al. Proportion of second cancers attributable to radiotherapy treatment in adults: A cohort study in the US SEER cancer registries. Lancet Oncol. 12, 353\u2013360 (2011).","journal-title":"Lancet Oncol."},{"key":"74840_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ctrv.2018.05.008","volume":"68","author":"AJM Rombouts","year":"2018","unstructured":"Rombouts, A. J. M. et al. Does pelvic radiation increase rectal cancer incidence? A systematic review and meta-analysis. Cancer Treat. Rev. 68, 136\u2013144 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"74840_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.ygyno.2008.12.039","volume":"113","author":"S Kumar","year":"2009","unstructured":"Kumar, S. et al. Second neoplasms in survivors of endometrial cancer: Impact of radiation therapy. Gynecol. Oncol. 113, 233\u2013239 (2009).","journal-title":"Gynecol. Oncol."},{"key":"74840_CR8","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/S0140-6736(00)02139-5","volume":"355","author":"CL Creutzberg","year":"2000","unstructured":"Creutzberg, C. L. et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355, 1404\u20131411 (2000).","journal-title":"Lancet"},{"key":"74840_CR9","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(09)62163-2","volume":"375","author":"RA Nout","year":"2010","unstructured":"Nout, R. A. et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. Lancet 375, 816\u2013823 (2010).","journal-title":"Lancet"},{"key":"74840_CR10","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2014.58.6693","volume":"33","author":"LM Wiltink","year":"2015","unstructured":"Wiltink, L. M. et al. No increased risk of second cancer after radiotherapy in patients treated for rectal or endometrial cancer in the randomized TME, PORTEC-1, and PORTEC-2 trials. J. Clin. Oncol. 33, 1640\u20131646 (2015).","journal-title":"J. Clin. Oncol."},{"key":"74840_CR11","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1002\/cncr.25067","volume":"116","author":"JD Wright","year":"2010","unstructured":"Wright, J. D. et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 116, 2486\u20132492 (2010).","journal-title":"Cancer"},{"key":"74840_CR12","doi-asserted-by":"crossref","unstructured":"Krasnow, R. E. et al. The impact of age at the time of radiotherapy for localized prostate cancer on the development of second primary malignancies. Urol. Oncol. 36, 500.e511\u2013500.e519 (2018).","DOI":"10.1016\/j.urolonc.2018.06.007"},{"key":"74840_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/curroncol28010035","volume":"28","author":"W Li","year":"2021","unstructured":"Li, W., Xiao, H., Xu, X. & Zhang, Y. The impact of radiotherapy on the incidence of secondary malignancies: A pan-cancer study in the US SEER cancer registries. Curr. Oncol. 28, 301\u2013316 (2021).","journal-title":"Curr. Oncol."},{"key":"74840_CR14","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.jclinepi.2013.01.013","volume":"66","author":"EA Stuart","year":"2013","unstructured":"Stuart, E. A., Lee, B. K. & Leacy, F. P. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J. Clin. Epidemiol. 66, S84\u2013S90 (2013).","journal-title":"J. Clin. Epidemiol."},{"key":"74840_CR15","doi-asserted-by":"publisher","first-page":"3836","DOI":"10.18632\/aging.204047","volume":"14","author":"K Huang","year":"2022","unstructured":"Huang, K. et al. Second primary malignancies in cervical cancer and endometrial cancer survivors: A population-based analysis. Aging (Albany NY) 14, 3836\u20133855 (2022).","journal-title":"Aging (Albany NY)"},{"key":"74840_CR16","doi-asserted-by":"publisher","first-page":"e2031661","DOI":"10.1001\/jamanetworkopen.2020.31661","volume":"4","author":"X Guan","year":"2021","unstructured":"Guan, X. et al. Association of radiotherapy for rectal cancer and second gynecological malignant neoplasms. JAMA Netw. Open 4, e2031661 (2021).","journal-title":"JAMA Netw. Open."},{"key":"74840_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.radonc.2017.01.009","volume":"123","author":"C Wang","year":"2017","unstructured":"Wang, C. et al. Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer. Radiother Oncol. 123, 133\u2013138 (2017).","journal-title":"Radiother Oncol."},{"key":"74840_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00404-019-05187-9","volume":"300","author":"K Papatla","year":"2019","unstructured":"Papatla, K., Houck, K. L., Hernandez, E., Chu, C. & Rubin, S. Second primary uterine malignancies after radiation therapy for cervical cancer. Arch. Gynecol. Obstet. 300, 389\u2013394 (2019).","journal-title":"Arch. Gynecol. Obstet."},{"key":"74840_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.radonc.2017.02.007","volume":"123","author":"R Warschkow","year":"2017","unstructured":"Warschkow, R. et al. Secondary malignancies after rectal cancer resection with and without radiation therapy: A propensity-adjusted, population-based SEER analysis. Radiother Oncol. 123, 139\u2013146 (2017).","journal-title":"Radiother Oncol."},{"key":"74840_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.4143\/crt.2014.326","volume":"48","author":"MC Lim","year":"2016","unstructured":"Lim, M. C. et al. Second primary cancer after diagnosis and treatment of cervical cancer. Cancer Res. Treat. 48, 641\u2013649 (2016).","journal-title":"Cancer Res. Treat."},{"key":"74840_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1097\/AOG.0b013e31819c842d","volume":"113","author":"JS Kwon","year":"2009","unstructured":"Kwon, J. S., Elit, L., Saskin, R., Hodgson, D. & Grunfeld, E. Secondary cancer prevention during follow-up for endometrial cancer. Obstet. Gynecol. 113, 790\u2013795 (2009).","journal-title":"Obstet. Gynecol."},{"key":"74840_CR22","doi-asserted-by":"publisher","first-page":"7018","DOI":"10.1038\/sj.onc.1206989","volume":"22","author":"AJ Sigurdson","year":"2003","unstructured":"Sigurdson, A. J. & Jones, I. M. Second cancers after radiotherapy: any evidence for radiation-induced genomic instability? Oncogene 22, 7018\u20137027 (2003).","journal-title":"Oncogene"},{"key":"74840_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0360-3016(03)00073-7","volume":"56","author":"EJ Hall","year":"2003","unstructured":"Hall, E. J. & Wuu, C. S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int. J. Radiat. Oncol. Biol. Phys. 56, 83\u201388 (2003).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"74840_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/genes2041033","volume":"2","author":"U Schneider","year":"2011","unstructured":"Schneider, U. Modeling the risk of secondary malignancies after radiotherapy. Genes (Basel) 2, 1033\u20131049 (2011).","journal-title":"Genes (Basel)"},{"key":"74840_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1874471011666171229123130","volume":"11","author":"R Yahyapour","year":"2018","unstructured":"Yahyapour, R. et al. Mechanisms of radiation bystander and non-targeted effects: Implications to radiation carcinogenesis and radiotherapy. Curr. Radiopharm. 11, 34\u201345 (2018).","journal-title":"Curr. Radiopharm"},{"key":"74840_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.canlet.2014.01.023","volume":"356","author":"S Havaki","year":"2015","unstructured":"Havaki, S. et al. The role of oxidative DNA damage in radiation induced bystander effect. Cancer Lett. 356, 43\u201351 (2015).","journal-title":"Cancer Lett."},{"key":"74840_CR27","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/cdd.2014.24","volume":"21","author":"R Lall","year":"2014","unstructured":"Lall, R. et al. Low-dose radiation exposure induces a HIF-1-mediated adaptive and protective metabolic response. Cell. Death Differ. 21, 836\u2013844 (2014).","journal-title":"Cell. Death Differ."},{"key":"74840_CR28","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/JCO.21.01841","volume":"40","author":"E Pasqual","year":"2022","unstructured":"Pasqual, E. et al. Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies. J. Clin. Oncol. 40, 1439\u20131449 (2022).","journal-title":"J. Clin. Oncol."},{"key":"74840_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000356115","volume":"93","author":"T Jin","year":"2014","unstructured":"Jin, T., Song, T., Deng, S. & Wang, K. Radiation-induced secondary malignancy in prostate cancer: A systematic review and meta-analysis. Urol. Int. 93, 279\u2013288 (2014).","journal-title":"Urol. Int."},{"key":"74840_CR30","doi-asserted-by":"publisher","first-page":"957608","DOI":"10.3389\/fonc.2022.957608","volume":"12","author":"G Yu","year":"2022","unstructured":"Yu, G. et al. Risk and prognosis of second corpus uteri cancer after radiation therapy for pelvic cancer: A population-based analysis. Front. Oncol. 12, 957608 (2022).","journal-title":"Front. Oncol."},{"key":"74840_CR31","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s12185-019-02620-2","volume":"109","author":"K Sasaki","year":"2019","unstructured":"Sasaki, K. et al. Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int. J. Hematol. 109, 545\u2013552 (2019).","journal-title":"Int. J. Hematol."},{"key":"74840_CR32","doi-asserted-by":"publisher","first-page":"100177","DOI":"10.1016\/j.ctarc.2020.100177","volume":"24","author":"C Natale","year":"2020","unstructured":"Natale, C., Leinwand, G., Zeineddine, F., Silberstein, J. L. & Krane, L. S. Does muscle invasive bladder cancer following pelvic radiotherapy portend worse prognosis? A seer-based study. Cancer Treat. Res. Commun. 24, 100177 (2020).","journal-title":"Cancer Treat. Res. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74840-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74840-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74840-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T14:04:00Z","timestamp":1729346640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74840-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74840"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74840-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,19]]},"assertion":[{"value":"16 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Since the data were de-identified and available to the public, the current study did not require ethics committee permission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"24623"}}